Scarica l'app Stockscreener
28.43
3.65%
1.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.43
Aprire:
$27.64
Volume 24 ore:
536.13K
Relative Volume:
0.31
Capitalizzazione di mercato:
$4.69B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
14.58
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+7.08%
1M Prestazione:
-6.11%
6M Prestazione:
-21.03%
1 anno Prestazione:
+7.57%
Intervallo 1D:
$27.51
$28.56
Intervallo di 1 settimana:
$26.07
$28.56
Portata 52W:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.42 | 4.38B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
151.68 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.70 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.14 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.71 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Live Scanner Shows Breakout on Alkermes plcMarket Surge Signal for Swing Traders Triggered - metal.it
Is Alkermes plc in a long term uptrendWealth Leverage Stock List - mustnews.co.kr
BlackRock increases stake in Alkermes to 17% - Investing.com India
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com Canada
Alkermes plc Included in Top Momentum ScanInvestment Strategy Designed for Capital Protection - metal.it
Chondrosarcoma Market: Epidemiology, Pipeline Products, - openPR.com
Alkermes plc Announces Pricing of New Term Loans - AOL.com
What markets is AAON Inc. expanding into Is Alkermes plc stock a good long term investment optionBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Alkermes plc stockUnmatched market gains - Jammu Links News
Is Alkermes plc a growth stock or a value stockInvest smarter with expert trading signals - Jammu Links News
What makes Alkermes plc stock price move sharplyInvest confidently with professional advice - Jammu Links News
Is Alkermes plc stock overvalued or undervaluedGet exclusive access to expert stock recommendations - Jammu Links News
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN
What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - Jammu Links News
Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - Jammu Links News
Needham & Company LLC Reaffirms "Buy" Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
How does Alkermes plc generate profit in a changing economyBuild capital through low-risk investments - Jammu Links News
What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - Jammu Links News
What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - Jammu Links News
How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - Jammu Links News
Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest
ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN
(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com
Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN
Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha
Alkermes stock price target raised to $42 from $40 at RBC Capital - Investing.com Nigeria
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey
Alkermes Beat Expectations With A Strong Second Quarter - Finimize
Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com
RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating - MarketScreener
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes: Q2 Earnings Snapshot - Norwalk Hour
Alkermes Reports Strong Q2 2025 Financial Results - TipRanks
Trading Bots Trigger Alerts on Alkermes plc ActivityDaily Smart Money Movement Monitor Activated - metal.it
Multi Factor Analysis Ranks Alkermes plc as Strong BuyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alkermes Earnings Call: Strong Growth and Promising Trials - TipRanks
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Alkermes price target lowered to $33 from $35 at BofA - TipRanks
Why Alkermes plc stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Alkermes Q2 2025 Earnings Call Transcript - MarketBeat
Published on: 2025-07-29 17:34:19 - metal.it
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Alkermes plc. SEC 10-Q Report - TradingView
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alkermes Plc Azioni (ALKS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):